US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bioinvent International AB

3.29

0.0000

Volume:- -

Turnover:- -

Market Cap:216.40M

PE:-6.92

High:3.29

Open:3.29

Low:3.29

Close:3.29

Loading ...

Overview Company News Filings

Resolutions at BioInvent's Annual General Meeting 2025

ACCESS Newswire

BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Cutaneous T-cell Lymphoma

ACCESS Newswire

BioInvent International AB: Interim Report January - March 2025

ACCESS Newswire

BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3

ACCESS Newswire

BioInvent International AB Publishes Annual Report 2024

ACCESS Newswire

BioInvent to Participate in Upcoming Investor Conferences

ACCESS Newswire

Notice to Annual General Meeting in BioInvent International AB

ACCESS Newswire

BioInvent’s anti-TNFR2 antibody BI-1808 showcased at the 16th Annual T-Cell Lymphoma Forum

ACCESS Newswire

BioInvent Receives FDA Orphan Drug Designation for BI-1808 for the Treatment of T-cell Lymphoma

ACCESS Newswire

BioInvent International AB: Year-End Report January 1 - December 31, 2024

ACCESS Newswire

Invitation to Presentation of BioInvent's Year-end Report 2024

ACCESS Newswire

BioInvent Achieves ISO 26000 Verification, Highlighting Commitment to ESG and Transparency

BioInvent Announces Promising Initial Efficacy Data from Triple Combination Arm of BI-1206, Rituximab and Calquence for the Treatment of non-Hodgkin's Lymphoma

BioInvent Announces Promising Data for BI-1910 as Single Agent from Phase 1 Study in Solid Tumors

BioInvent Announces First Patient Enrolled in Phase 1b/2a Study of BI-1607 in Combination with Ipilimumab and KEYTRUDA (Pembrolizumab) in Patients with Unresectable or Metastatic Melanoma

BioInvent Appoints Ashley Robinson as SVP Strategy & Finance to Lead US Expansion

Exploring High Growth Tech Stocks This November 2024

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BOVNF/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BOVNF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BOVNF\",,,,,undefined,":{"symbol":"BOVNF","market":"US","secType":"STK","nameCN":"Bioinvent International AB","latestPrice":3.2886,"timestamp":1749758400000,"preClose":3.2886,"halted":0,"volume":0,"delay":15,"floatShares":32815306,"shares":65804362,"eps":-0.475308,"marketStatus":"Pre-Mkt","change":0,"latestTime":"06-12 16:00:00 EDT Delay","open":3.2886,"high":3.2886,"low":3.2886,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.475308,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1749821400000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":3.2886,"volumeRatio":4.989178601437883},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BOVNF\",,,,,undefined,":{"symbol":"BOVNF","floatShares":32815306,"roa":"-24.65%","roe":"-39.11%","lyrEps":-0.499403,"volumeRatio":4.989178601437883,"shares":65804362,"dividePrice":0,"high":3.2886,"amplitude":0,"preClose":3.2886,"low":3.2886,"week52Low":3.2886,"pbRate":"2.33","psRate":"46.11","week52High":4.7,"institutionHeld":0,"latestPrice":3.2886,"eps":-0.475308,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.475308,"open":3.2886,"prevYearClose":4.7,"prevWeekClose":4.7,"prevMonthClose":4.7,"prevQuarterClose":4.7,"fiveDayClose":4.7,"twentyDayClose":4.7,"sixtyDayClose":4.7},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BOVNF\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531768662","title":"Resolutions at BioInvent's Annual General Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531768662","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531768662?lang=en_us&edition=fundamental","pubTime":"2025-04-29 23:15","pubTimestamp":1745939700,"startTime":"0","endTime":"0","summary":"LUND, SWEDEN / ACCESS Newswire / April 29, 2025 / The Annual General Meeting  of BioInvent International AB   resolved to re-elect the Board members Natalie Berner, Kristoffer Bissessar, Thomas Hecht, Leonard Kruimer, Laura Lassouw-Polman, Nanna Lüneborg, Vincent Ossipow and Bernd Seizinger and to implement a long-term incentive program.The AGM voted in favor of adopting the income statements and balance sheets for the Group and the parent company for the financial year 2024 and decided that no dividend should be declared for the financial year 2024.The AGM resolved to adopt the Board's report regarding compensation pursuant to Chapter 8, Section 53 a of the Swedish Companies Act.Last, the AGM authorized the Board to resolve on the issue of new shares, on one or several occasions during the period up to the ne","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/resolutions-bioinvents-annual-general-meeting-151500582.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BOVNF"],"gpt_icon":0},{"id":"2531557200","title":"BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Cutaneous T-cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2531557200","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531557200?lang=en_us&edition=fundamental","pubTime":"2025-04-29 18:15","pubTimestamp":1745921700,"startTime":"0","endTime":"0","summary":"LUND, SE / ACCESS Newswire / April 29, 2025 / BioInvent International AB  , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that the U.S. Food and Drug Administration  has granted Fast Track Designation to BI-1808, a first-in-class anti-TNFR2 antibody, for the treatment of adults with relapsed or refractory mycosis fungoides and Sézary syndrome, subtypes of cutaneous T-cell lymphoma . Fast Track Designation  is intended to facilitate the development and review of drugs that treat serious conditions.About Phase 1/2a studyDuring the first part of the Phase 1/2a study  the safety, tolerability, and potential signs of efficacy of BI-1808 as a single agent  and in combination with the anti-PD-1 therapy pembrolizumab  are evaluated in patients with advanced solid tumors and T-cell lymphoma. The efficacy of BI-1808 as single agent is currently explored in the Phase 2a part of the tria","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-receives-fda-fast-track-101500462.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FAST","BK4139","SD","PR","CR","BK4213","BK4161","BOVNF"],"gpt_icon":0},{"id":"2531229051","title":"BioInvent International AB: Interim Report January - March 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531229051","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531229051?lang=en_us&edition=fundamental","pubTime":"2025-04-29 14:20","pubTimestamp":1745907600,"startTime":"0","endTime":"0","summary":"LUND, SE / ACCESS Newswire / April 29, 2025 / BioInvent International . \"The first quarter of 2025 was a highly productive period across clinical development, regulatory milestones, and strategic partnerships - positioning us for strong momentum through the remainder of the year.\"- Martin Welschof CEO of BioInvent. Phase 1 data of the company's second anti-TNFR2 antibody BI-1910 as monotherapy for the treatment of solid tumors. BioInvent achieved ISO 26000 Verification, highlighting commitment to ESG and transparency. Composition of matter patent for the lead anti-TNFR2 antibody BI-1808 granted in Japan. It also covers the use of the antibody in the treatment of cancer. About BioInventBioInvent International AB  is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-international-ab-interim-report-062000414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4022","BK4590","AB","BK4598","BOVNF","BK4139","LU0128526141.USD","BK4232","R","LU0029874061.USD","BK4135"],"gpt_icon":0},{"id":"2525248895","title":"BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3","url":"https://stock-news.laohu8.com/highlight/detail?id=2525248895","media":"ACCESS Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525248895?lang=en_us&edition=fundamental","pubTime":"2025-04-08 19:15","pubTimestamp":1744110900,"startTime":"0","endTime":"0","summary":"LUND, SWEDEN / ACCESS Newswire / April 8, 2025 / BioInvent International AB  , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that it has earned a 1 million USD milestone payment, following Takeda's  initiation of Phase 3 clinical trial of mezagitamab , identified from BioInvent's proprietary n-CoDeR antibody library. The study is evaluating this potential best-in-class anti-CD83 monoclonal antibody for persistent or chronic primary immune thrombocytopenia .\"We are excited to see mezagitamab progress into Phase 3 trials, marking a significant step for Takeda and our n-CoDeR platform,\" said Martin Welschof, Chief Executive Officer of BioInvent. \"This milestone not only validates the consistent high quality of drug candidates identified from our n-CoDeR antibody library, but it also highlights the success of our out-licensing strategy and its ability to drive real-world impact t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-receives-milestone-payment-takeda-111500286.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BOVNF","TAK","BK4007","XOMA","ITP","BK4199","BK4139"],"gpt_icon":0},{"id":"2524327139","title":"BioInvent International AB Publishes Annual Report 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2524327139","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524327139?lang=en_us&edition=fundamental","pubTime":"2025-04-04 16:20","pubTimestamp":1743754800,"startTime":"0","endTime":"0","summary":"LUND, SE / ACCESS Newswire / April 4, 2025 / BioInvent International AB  , a biotech company focused on the discovery and development of novel and first-in-class immunomodulatory antibodies for cancer immunotherapy, today announced that the Annual Report for 2024 has been published. The Annual Report is attached to this press release in pdf format and is available on the company's website www.bioinvent.com .About BioInventBioInvent International AB  is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing l","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-international-ab-publishes-annual-082000529.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0029874061.USD","BK4598","BK4139","AB","BK4590","LU0128526141.USD","BOVNF","BK4135"],"gpt_icon":0},{"id":"2524167450","title":"BioInvent to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2524167450","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524167450?lang=en_us&edition=fundamental","pubTime":"2025-04-01 17:20","pubTimestamp":1743499200,"startTime":"0","endTime":"0","summary":"LUND, SE / ACCESS Newswire / April 1, 2025 / BioInvent International AB  , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that during April, the Company management team will participate in the following upcoming investor conferences:. Van Lanschot Kempen Life Sciences ConferenceFormat: One-on-one meetingsDate: April 2Location: Amsterdam, The Netherlands. Stifel Virtual Targeted Oncology ForumFormat: Corporate presentation and one-on-one meetings Date: April 8-9. Corporate presentation April 9 at 11:30 am EDT Location: Virtual. About BioInventBioInvent International AB  is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-participate-upcoming-investor-conferences-092000546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BOVNF"],"gpt_icon":0},{"id":"2522010593","title":"Notice to Annual General Meeting in BioInvent International AB","url":"https://stock-news.laohu8.com/highlight/detail?id=2522010593","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522010593?lang=en_us&edition=fundamental","pubTime":"2025-03-25 17:20","pubTimestamp":1742894400,"startTime":"0","endTime":"0","summary":"LUND, SE / ACCESS Newswire / March 25, 2025 / BioInvent International  The shareholders of BioInvent International AB , Reg. No 556537-7263, are hereby invited to attend the Annual General Meeting to be held at 4.00 p.m., 29 April 2025 at Elite Hotel Ideon on Scheelevgen 27 in Lund, Sweden.A shareholder who wishes to attend the meeting room or who wishes to exercise its voting rights by voting in advance by post must be recorded in the share register maintained by Euroclear Sweden AB , as of 17 April 2025; and must. If the shareholder is represented by proxy, a written and dated power of attorney signed by the shareholder must be issued for the representative. Forms of power of attorney are available on the company's website, www.bioinvent.com . If the shareholder is a legal entity, a certificate of incorporation, or corresponding authorization document, must be attached. The power of attorney together with any registration certificate and other authorization documents should be sent t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/notice-annual-general-meeting-bioinvent-092000234.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4590","BOVNF","BK4135","BK4139","AB","BK4598","LU0029874061.USD","LU0128526141.USD"],"gpt_icon":0},{"id":"2521200024","title":"BioInvent’s anti-TNFR2 antibody BI-1808 showcased at the 16th Annual T-Cell Lymphoma Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2521200024","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521200024?lang=en_us&edition=fundamental","pubTime":"2025-03-21 15:20","pubTimestamp":1742541600,"startTime":"0","endTime":"0","summary":"BioInvent International AB  , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that one of the company's lead program; BI-1808 as monotherapy in Cutaneous T Cell Lymphoma  will be presented at the 16th Annual T-Cell Lymphoma Forum held March 20-22, 2025 in La Jolla, California.The data, previously disclosed in a press release in September 2024, will be featured in a poster presentation highlighting the early efficacy of BI-1808 monotherapy in the ongoing Phase 2a dose expansion study in CTCL. So far three partial responses  and one stable disease  out of four evaluable patients have been reported. The Company anticipates reporting additional data from the study in mid-2025.BI-1808, a first-in-class anti-TNFR2 antibody, was recently granted Orphan Drug Designation by the U.S. Food and Drug Administration  for the treatment of TCL.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-anti-tnfr2-antibody-bi-072000423.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CR","BOVNF","BK4179","FET","BK4139","BK4213","SD","PR","BK4161"],"gpt_icon":0},{"id":"2520107816","title":"BioInvent Receives FDA Orphan Drug Designation for BI-1808 for the Treatment of T-cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2520107816","media":"ACCESS Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520107816?lang=en_us&edition=fundamental","pubTime":"2025-03-20 15:20","pubTimestamp":1742455200,"startTime":"0","endTime":"0","summary":"LUND, SE / ACCESS Newswire / March 20, 2025 / BioInvent International AB  , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that the U.S. Food and Drug Administration  has granted Orphan Drug Designation  for BI-1808, a first-in-class anti-TNFR2 antibody for the treatment of T-cell Lymphoma .\"We are excited to receive the FDA's Orphan Drug Designation for the treatment of TCL. This designation along with the recently announced positive Phase 2a data in CTCL reinforces our continued progress and commitment to developing BI-1808 as a potential novel class of immunomodulatory agents for TCL\", said Martin Welschof, Chief Executive Officer of BioInvent. \"We look forward to working closely with the regulatory agencies to accelerate the development of BI-1808 and bring this innovative treatment to patients who are in great need of new treatment options.\". About the Phase 1/2a studyDur","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-receives-fda-orphan-drug-072000957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SD","BOVNF","CR","BK4139","PR","ODD","BK4183","BK4213","BK4161"],"gpt_icon":0},{"id":"2514251528","title":"BioInvent International AB: Year-End Report January 1 - December 31, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2514251528","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514251528?lang=en_us&edition=fundamental","pubTime":"2025-02-27 15:30","pubTimestamp":1740641400,"startTime":"0","endTime":"0","summary":"LUND, SWEDEN / ACCESS Newswire / February 27, 2025 / BioInvent International  \"2024 was a year with several exciting developments reported from across our broad portfolio of clinical programs. We now have two Phase 2 and four Phase 1 trials running in our six clinical programs leveraging the TNFR2 and FcyRIIB targets. Throughout the year, we pursued building our business by expanding our management team and signing important clinical collaboration and supply agreements with key partners.\" - Martin Welschof CEO of BioInvent.First patient enrolled in Phase 1b/2a study of the company's second anti-FcyRIIB antibody, BI-1607, in combination with ipilimumab and KEYTRUDA  in patients with unresectable or metastatic melanoma. Expanded management team with appointment of Ashley Robinson as SVP of Strategy and Finance. BioInvent achieved ISO 26000 Verification, highlighting commitment to ESG and transparency. ESMO presentations highlighting progress from the Phase 1 trial of BI-1910 monotherapy ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-international-ab-end-report-073000160.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0058720904.USD","IE0002141913.USD","IE00BBT3K403.USD","LU0965509101.SGD","SG9999001176.SGD","IE00BLSP4452.SGD","AB","LU1989771016.USD","BOVNF","SG9999001176.USD","LU1934455863.HKD","LU0320765489.SGD","LU1430594728.SGD","SG9999002232.USD","LU0320765646.SGD","SG9999014575.USD","LU0265550946.USD","LU0985320562.USD","LU0266013472.USD","BK4007","LU2023250843.SGD","LU1974910355.USD","BK4588","LU1116320901.HKD","SG9999001440.SGD","SG9999014567.USD","LU1116320737.USD","BK4585","LU1057294990.SGD","LU2324357040.USD","R","IE00B2B36J28.USD","LU2112291526.USD","LU2089984988.USD","SG9999002224.SGD","LU0265550359.USD","LU1093756325.SGD","IE00B1BXHZ80.USD","IE00BSNM7G36.USD","IE0009355771.USD","BK4135","LU0006306889.USD","LU0238689110.USD","LU0965508806.USD","LU1941712348.USD","LU2461242641.AUD","LU2468319806.SGD","SG9999015341.SGD","IE00B4R5TH58.HKD"],"gpt_icon":1},{"id":"2514091043","title":"Invitation to Presentation of BioInvent's Year-end Report 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2514091043","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514091043?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:25","pubTimestamp":1740489900,"startTime":"0","endTime":"0","summary":"LUND, SE / ACCESS Newswire / February 25, 2025 / BioInvent International AB   invites investors, analysts, and the press to a presentation of the Year-end report 2024 on February 27 at 4:00 pm CET. The report will be published at 8:00 am CET the same day.BioInvent's CEO Martin Welschof will present the report together with CFO Stefan Ericsson. The presentation will be held in English.The conference call will be made available on the company website after the call.About BioInventBioInvent International AB  is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/invitation-presentation-bioinvents-end-report-132500465.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BOVNF","BK4139"],"gpt_icon":0},{"id":"2502785475","title":"BioInvent Achieves ISO 26000 Verification, Highlighting Commitment to ESG and Transparency","url":"https://stock-news.laohu8.com/highlight/detail?id=2502785475","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502785475?lang=en_us&edition=fundamental","pubTime":"2025-01-10 19:30","pubTimestamp":1736508600,"startTime":"0","endTime":"0","summary":"LUND, SWEDEN / ACCESSWIRE / January 10, 2025 / BioInvent International . BioInvent International AB  , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has achieved ISO 26000 verification, an internationally recognized standard. This achievement highlights BioInvent's dedication to environmental, social, and governance  principles and transparent business practices.ISO 26000 serves as a comprehensive guideline for organizations committed to operating responsibly in areas such as environmental sustainability, labor practices, human rights, and community involvement. By meeting this standard, BioInvent has demonstrated its ability to integrate sustainability into its business strategies and daily operations.About BioInventBioInvent International AB  is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-achieves-iso-26000-verification-113000637.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ISO","BK4139","BOVNF","ESG"],"gpt_icon":0},{"id":"2501719058","title":"BioInvent Announces Promising Initial Efficacy Data from Triple Combination Arm of BI-1206, Rituximab and Calquence for the Treatment of non-Hodgkin's Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2501719058","media":"ACCESSWIRE","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501719058?lang=en_us&edition=fundamental","pubTime":"2025-01-08 15:20","pubTimestamp":1736320800,"startTime":"0","endTime":"0","summary":"LUND, SWEDEN / ACCESSWIRE / January 8, 2025 / BioInvent International . The first two patients enrolled in the Phase 2a study triplet arm combining BI-1206 with rituximab and Calquence responded to treatment. The preliminary data demonstrates that the combination treatment is well tolerated with the two enrolled patients already showing clinical responses. One patient has obtained a complete response , and one patient shows a partial response . Patient enrollment remains on schedule. Further Phase 2a data are expected by mid-2025.In addition, the Phase 1/2a study of BI-1206 in combination with MSD's  anti-PD-1 therapy KEYTRUDA  in heavily pre-treated patients with solid tumors continues to progress. The subcutaneous administration of BI-1206 has been well-tolerated with no notable injection reactions. Given the beneficial safety and tolerability profile observed to date, an additional dose cohort with increased dose frequency has been added to the Phase 1 part to further characterize t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-announces-promising-initial-efficacy-072000078.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0861579265.USD","IE00B4R5TH58.HKD","LU2023250843.SGD","LU0289739699.SGD","CR","LU0006306889.USD","LU1116320737.USD","IE00B1BXHZ80.USD","LU0965509101.SGD","SD","LU1023059063.AUD","LU0211331839.USD","BOVNF","IE00BMPRXQ63.HKD","LU1037948541.HKD","IE000M9KFDE8.USD","LU1037948897.HKD","LU1983299246.USD","LU2468319806.SGD","LU1291159041.SGD","BK4007","SG9999015341.SGD","PR","LU0070302665.USD","LU0965509283.SGD","LU1066051498.USD","LU1585245621.USD","LU0122379950.USD","LU1066051811.HKD","IE0009355771.USD","LU0234572021.USD","LU1934455194.USD","LU1989772923.USD","LU1917777945.USD","SG9999014575.USD","LU0203345920.USD","LU1061106388.HKD","BK4585","IE0002141913.USD","MRK","SG9999014559.SGD","LU1699723380.USD","LU2461242641.AUD","IE00BMPRXR70.SGD","SG9999015358.SGD","LU0265550359.USD","SG9999002224.SGD","LU0208291251.USD","LU1571399168.USD"],"gpt_icon":1},{"id":"2501050719","title":"BioInvent Announces Promising Data for BI-1910 as Single Agent from Phase 1 Study in Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2501050719","media":"ACCESSWIRE","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501050719?lang=en_us&edition=fundamental","pubTime":"2025-01-08 15:20","pubTimestamp":1736320800,"startTime":"0","endTime":"0","summary":"LUND, SWEDEN / ACCESSWIRE / January 8, 2025 / BioInvent International . BI-1910 single agent Phase 1 Part A dose escalation has been completed and reached a biologically active dose level. Data show stable disease as best clinical response with no notable adverse events even at the highest doses tested.Phase 1 part B evaluating BI-1910 in combination with MSD's anti-PD-1 therapy, KEYTRUDA  initiated. As reported in September 2024, preliminary results from the BI-1808 monotherapy study showed that three out of four evaluable patients achieved partial response  in the CTCL cohort of patients who had progressed after standard therapy. These responses are currently ongoing and deepening. New clinical sites have been opened and the enrollment rate in this c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-announces-promising-data-bi-072000027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0234572021.USD","IE00B1BXHZ80.USD","LU1585245621.USD","SG9999015358.SGD","IE000M9KFDE8.USD","IE00B4R5TH58.HKD","LU0122379950.USD","SG9999014559.SGD","SG9999015341.SGD","LU1917777945.USD","LU0265550359.USD","LU1037948897.HKD","LU2461242641.AUD","LU0006306889.USD","LU1066051811.HKD","LU1983299246.USD","LU1066051498.USD","BK4007","LU1934455194.USD","LU1934455277.USD","IE0009355771.USD","LU1061106388.HKD","LU1571399168.USD","LU0965509283.SGD","LU1989772923.USD","SG9999002224.SGD","LU0208291251.USD","LU0070302665.USD","LU0861579265.USD","SG9999014575.USD","LU1023059063.AUD","LU0211331839.USD","LU1116320737.USD","LU2023250843.SGD","LU0203345920.USD","CR","LU1291159041.SGD","BK4516","LU0965509010.AUD","LU2468319806.SGD","BK4585","PR","LU0965509101.SGD","BOVNF","IE0002141913.USD","LU1037948541.HKD","MRK","LU0289739699.SGD","LU1699723380.USD","SD"],"gpt_icon":0},{"id":"2490887557","title":"BioInvent Announces First Patient Enrolled in Phase 1b/2a Study of BI-1607 in Combination with Ipilimumab and KEYTRUDA (Pembrolizumab) in Patients with Unresectable or Metastatic Melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2490887557","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490887557?lang=en_us&edition=fundamental","pubTime":"2024-12-12 15:20","pubTimestamp":1733988000,"startTime":"0","endTime":"0","summary":"Study to evaluate safety and anti-tumoral activity of anti-FcgRIIB antibody BI-1607 with anti-CTLA-4: ipilimumab, in combination with MSD's ( anti-PD-1 therapy, KEYTRUDA (pembrolizumab); initial data expected in H2 2025. Data from Phase 1 study in combination with trastuzumab previously demonstrated BI-1607 is safe, well tolerated and achieves full receptor occupancy during the treatment interval at several dose levels; preclinical data show BI-1607 enables lower anti-CTLA-4 dosing with improved survival. LUND, SE / ACCESSWIRE / December 12, 2024 / BioInvent International AB  , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has enrolled the first patient in the Phase1b/2a study evaluating the safety and anti-tumoral activity of its second FcyRIIB-blocking antibody BI-1607 in combination with ipilimumab and KEYTRUDA  in patients with unresectable or metastatic melanoma.BI-16","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/3wX2YGGMRe8O2W1jYdxcfA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/46e2cb332e043fe93eb50efbeae98e79","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/3wX2YGGMRe8O2W1jYdxcfA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/46e2cb332e043fe93eb50efbeae98e79"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-announces-first-patient-enrolled-072000380.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BFTCPJ56.SGD","BOVNF","LU1057294990.SGD","LU2468319806.SGD","BK4559","LU0266013472.USD","LU1066051498.USD","LU1941712264.USD","LU1989772840.SGD","LU0106261372.USD","IE00BJT1NW94.SGD","LU2023250504.SGD","LU0985320562.USD","IE00BLSP4452.SGD","LU1066053197.SGD","LU0238689110.USD","IE00B1BXHZ80.USD","LU0070302665.USD","LU1116320901.HKD","LU2089984988.USD","LU0203345920.USD","LU0211331839.USD","SG9999015341.SGD","BK4533","BK4550","LU1571399168.USD","LU0965508806.USD","LU0006306889.USD","LU0208291251.USD","LU1093756325.SGD","LU2106854487.HKD","SG9999015358.SGD","LU0203347892.USD","LU2361044949.HKD","LU0265550946.USD","LU2023250843.SGD","LU0289739699.SGD","LU1116320737.USD","LU0320765489.SGD","LU1585245621.USD","SG9999014575.USD","LU1061106388.HKD","LU1430594728.SGD","SG9999002224.SGD","SG9999001176.SGD","LU0265550359.USD","SG9999002232.USD","LU2324357040.USD","MRK","LU0965509283.SGD"],"gpt_icon":0},{"id":"2488944772","title":"BioInvent Appoints Ashley Robinson as SVP Strategy & Finance to Lead US Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2488944772","media":"ACCESSWIRE","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488944772?lang=en_us&edition=fundamental","pubTime":"2024-12-03 15:30","pubTimestamp":1733211000,"startTime":"0","endTime":"0","summary":"Appointment strengthens BioInvent's presence and strategy in the US. Mr Robinson brings broad experience from the US and global financial markets. BioInvent is in a pivotal stage of development with upcoming important data readouts from three of its six antibody programs around year-end 2024, and an additional seven major data readouts expected during 2025 from four different clinical assets.LUND, SWEDEN and BOSTON, MA / ACCESSWIRE / December 3, 2024 /BioInvent International AB  , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces the appointment of Ashley Robinson as SVP Strategy & Finance, effective as of today. In this role, Mr. Robinson will spearhead efforts to strengthen BioInvent's presence and strategy in the US.The Company generates revenues from research collaborations and license agreements with multiple to","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/3wX2YGGMRe8O2W1jYdxcfA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/46e2cb332e043fe93eb50efbeae98e79","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/3wX2YGGMRe8O2W1jYdxcfA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/46e2cb332e043fe93eb50efbeae98e79"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-appoints-ashley-robinson-svp-073000928.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BOVNF","BK4139"],"gpt_icon":0},{"id":"2486778637","title":"Exploring High Growth Tech Stocks This November 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2486778637","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486778637?lang=en_us&edition=fundamental","pubTime":"2024-11-25 14:11","pubTimestamp":1732515119,"startTime":"0","endTime":"0","summary":"As global markets show resilience with major U.S. indexes approaching record highs and smaller-cap indexes outperforming, investor sentiment remains cautiously optimistic amid geopolitical tensions and economic uncertainties. In this environment, identifying high-growth tech stocks requires a focus on companies that demonstrate strong fundamentals, innovative capabilities, and adaptability to evolving market conditions.Click here to see the full list of 1300 stocks from our High Growth Tech and AI Stocks screener.BioInvent International, despite its current unprofitability and a challenging revenue base of SEK 39M, is navigating through a transformative phase with significant R&D investments. The company's commitment to innovation is evident as it reported an impressive forecasted annual revenue growth rate of 90.4%, outpacing the Swedish market's stagnant growth. Additionally, earnings are expected to surge by 108.6% annually. Recent clinical trials, such as the promising results from","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/3wFOxca.gMo3EgB9BjBM9g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/41bdd0c670f621394929d5266c5d6c72","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/3wFOxca.gMo3EgB9BjBM9g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/41bdd0c670f621394929d5266c5d6c72"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exploring-high-growth-tech-stocks-061159997.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BOVNF","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BOVNF\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-04-24","symbol":"BOVNF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1713931200000,"reportTimeType":"","actualEps":null},{"date":"2022-10-27","symbol":"BOVNF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1666857600000,"name":null,"time":"Pre-Market","dateTimestamp":1666843200000,"actualEps":null},{"date":"2022-08-25","symbol":"BOVNF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1661414400000,"name":null,"time":"Pre-Market","dateTimestamp":1661400000000,"actualEps":null},{"date":"2022-04-27","symbol":"BOVNF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1651046400000,"name":null,"time":"Pre-Market","dateTimestamp":1651032000000,"actualEps":null},{"market":"US","date":"2020-12-14","symbol":"BOVNF","defaultRemindTime":1607956200000,"type":"split","dateTimestamp":1607922000000,"forFactor":25,"toFactor":1,"ratio":25}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BOVNF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BOVNF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1743480000000}}}